P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), A. Krishnan(City of Hope), Surbhi Sidana(Palo Alto University), Jesús F. San Miguel(Clinica Universidad de Navarra), Ajay K. Nooka(Emory University), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Lionel Karlin(Hôpital Lyon Sud), Alfred L. Garfall(University of Pennsylvania), Albert Oriol(Institut Català d'Oncologia), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Philippe Moreau(Centre National de la Recherche Scientifique), MV Mateos(Instituto de Investigación Biomédica de Salamanca), Ajai Chari(Icahn School of Medicine at Mount Sinai), N. W. van de Donk(Amsterdam University Medical Centers), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k